We are live on ! Find out more
UROV

Urovant Sciences Ltd.
UROV

Delisted

UROV was delisted on the 26th of March, 2021.

Back to rankings

25 hedge funds and large institutions have $62.4M invested in Urovant Sciences Ltd. in 2020 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 2

14% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 7

4% more funds holding

Funds holding: 24 → 25 (+1)

7% less capital invested

Capital invested by funds: $67M → $62.4M (-$4.59M)

Holders
25
Holders Change
+1
Holders Change %
+4.17%
% of All Funds
0.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
8
Reduced
2
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PHS
Pekin Hardy Strauss
Illinois
+$1.42M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$1.32M
3
Renaissance Technologies
Renaissance Technologies
New York
+$1.05M
4
BBVA
Banco Bilbao Vizcaya Argentaria
Spain
+$978K
5
Northern Trust
Northern Trust
Illinois
+$421K

Top Sellers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$8.46M
2
First Manhattan
First Manhattan
New York
-$2.11M
3
PWAM
Park West Asset Management
California
-$2.07M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.73M
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$86.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
1
Perceptive Advisors
New York
$23.3M – – –
BBA
2
Baker Bros. Advisors
New York
$9.84M – – –
Fidelity Investments
3
Fidelity Investments
Massachusetts
$7.01M -$1.73M -180,800 -20%
Alyeska Investment Group
4
Alyeska Investment Group
Illinois
$6.11M +$1.32M +137,721 +29%
PHS
5
Pekin Hardy Strauss
Illinois
$3.81M +$1.42M +148,316 +62%
BlackRock
6
BlackRock
New York
$3.05M +$44.3K +4,617 +2%
SB
7
Samsara BioCapital
California
$1.55M – – –
Vanguard Group
8
Vanguard Group
Pennsylvania
$1.29M – – –
Renaissance Technologies
9
Renaissance Technologies
New York
$1.08M +$1.05M +109,328 New
BBVA
10
Banco Bilbao Vizcaya Argentaria
Spain
$1M +$978K +101,975 New
WCM
11
Wildcat Capital Management
New York
$932K – – –
Geode Capital Management
12
Geode Capital Management
Massachusetts
$878K +$65.9K +6,875 +8%
Northern Trust
13
Northern Trust
Illinois
$581K +$421K +43,920 +290%
KCM
14
Kornitzer Capital Management
Kansas
$503K – – –
LA
15
LVW Advisors
New York
$382K +$48K +5,000 +15%
Millennium Management
16
Millennium Management
New York
$340K +$332K +34,578 New
PCS
17
Personal CFO Solutions
New Jersey
$338K +$330K +34,388 New
MWNA
18
Marshall Wace North America
New York
$153K – – –
First Trust Advisors
19
First Trust Advisors
Illinois
$151K +$11K +1,144 +8%
VWM
20
Vigilare Wealth Management
Arizona
$100K +$97.8K +10,200 New
Wells Fargo
21
Wells Fargo
California
$6K +$4.8K +500 +980%
TRCT
22
Tower Research Capital (TRC)
New York
$6K +$6.22K +649 New
Royal Bank of Canada
23
Royal Bank of Canada
Ontario, Canada
$3K -$86.1K -8,975 -96%
UBS Group
24
UBS Group
Switzerland
$3K +$3.16K +329 New
Adage Capital Partners
25
Adage Capital Partners
Massachusetts
– -$8.46M -917,094 Closed
1
2

UROV Hedge Fund Activity: Q2 2020 in Review

25 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Urovant Sciences Ltd. (UROV) for Q2 2020, worth a combined $62.4M — down 6.9% from $67M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new UROV positions and 7 closed out — a net gain of 1 holder — while 8 added to existing stakes and 2 trimmed.

The largest buyer was Pekin Hardy Strauss, adding an estimated $1.42M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $8.46M sold.

  • 25 institutional investors held Urovant Sciences Ltd. (UROV) as of Q2 2020, up from 24 in Q1 2020.
  • Funds reported $62.4M of Urovant Sciences Ltd. stock for Q2 2020, down 6.9% quarter-over-quarter.
  • 8 funds opened new Urovant Sciences Ltd. positions in Q2 2020 and 7 closed out, a net change of +1 holder.
  • The largest Urovant Sciences Ltd. buyer in Q2 2020 was Pekin Hardy Strauss, an estimated $1.42M added.
  • The largest Urovant Sciences Ltd. seller in Q2 2020 was Adage Capital Partners, an estimated $8.46M sold.

Based on aggregated 13F filings for Q2 2020.